Literature DB >> 2510962

Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.

R Schulz1, K H Antonin, E Hoffmann, M Jedrychowski, E Nilsson, C Schick, P R Bieck.   

Abstract

The effect of the monoamine oxidase inhibitor selegiline on tyramine metabolism and intravenous and oral tyramine pressor sensitivity was studied in healthy subjects. After oral doses of tyramine, which caused systolic blood pressure to increase by 30 mm Hg, we determined plasma concentrations of p-hydroxyphenylacetic acid (HPAA) and of conjugated and unconjugated tyramine. When 20 mg/day of selegiline was administered, the AUCspec of HPAA decreased from 86% to 64% and the AUCspec of conjugated tyramine increased from 13% to 35% of the sum of total tyramine and HPAA. Pressor sensitivity was enhanced more with oral administration of tyramine than with intravenous administration of tyramine. After the drug was discontinued, initial values were reached within 4 days (one subject) and 2 weeks (two subjects). Fifty-five percent of the selegiline dose was eliminated in urine as amphetamine and methamphetamine. The findings support the assumption that selegiline does not selectively inhibit monoamine oxidase-B (MAO-B) when administered in doses of 20 mg/day and higher.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2510962     DOI: 10.1038/clpt.1989.181

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

1.  Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease.

Authors:  Matthias Löhle; Heinz Reichmann
Journal:  BMC Neurol       Date:  2011-09-22       Impact factor: 2.474

2.  Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids.

Authors:  K Laine; M Anttila; A Helminen; H Karnani; R Huupponen
Journal:  Br J Clin Pharmacol       Date:  1999-03       Impact factor: 4.335

Review 3.  Type A monoamine oxidase and serotonin are coordinately involved in depressive disorders: from neurotransmitter imbalance to impaired neurogenesis.

Authors:  Makoto Naoi; Wakako Maruyama; Masayo Shamoto-Nagai
Journal:  J Neural Transm (Vienna)       Date:  2017-03-14       Impact factor: 3.575

4.  Tyramine pressor sensitivity in healthy subjects during combined treatment with moclobemide and selegiline.

Authors:  A Korn; B Wagner; E Moritz; J Dingemanse
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

5.  Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327.

Authors:  C J Bench; G W Price; A A Lammertsma; J C Cremer; S K Luthra; D Turton; R J Dolan; R Kettler; J Dingemanse; M Da Prada
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 6.  Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease.

Authors:  P Chrisp; G J Mammen; E M Sorkin
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

Review 7.  Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide.

Authors:  M Mayersohn; T W Guentert
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

8.  A review of the literature on the selegiline transdermal system: an effective and well-tolerated monoamine oxidase inhibitor for the treatment of depression.

Authors:  Larry Culpepper; Lawrence J Kovalick
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

9.  Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease.

Authors:  Bradley J Robottom
Journal:  Patient Prefer Adherence       Date:  2011-01-20       Impact factor: 2.711

10.  Transdermal selegiline for the treatment of major depressive disorder.

Authors:  Kelly C Lee; Jack J Chen
Journal:  Neuropsychiatr Dis Treat       Date:  2007       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.